Munich

• Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended recruitment
  2023-507187-39-00 5 2023-03-23 High-Risk Non-muscle-invasive Bladder Cancer
• "Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Children with Partial-onset (Focal) Seizures " Ended recruitment
  2023-506841-52-00 5 2023-03-22 partial-onset (focal) seizures
• A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate pol … Ended recruitment
  2024-513949-37-00 4 2023-03-16 previously untreated aggressive B-cell lymphoma
• Phase 2 Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer Ended recruitment
  2023-509583-22-00 4 2023-03-14 Neoplasms, Rectal
• A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Ended recruitment
  2024-514173-22-00 5 2023-02-28 Cystic Fibrosis
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C … Ended recruitment
  2023-505552-22-00 5 2023-02-24 Stage I-III Triple-negative Breast Cancer with residual invasive disea
• Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarci … Ended recruitment
  2024-513610-34-00 4 2023-02-13 HER2-positive, localized esophagogastric adenocarcinoma
• A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection Ended recruitment
  2022-501901-10-00 6 2023-02-06 Chronic Hepatitis D Infection
• A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years o … Ended recruitment
  2023-504277-20-00 5 2023-01-30 Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorde
• Multicenter, prospective, double-blind, randomized, three-armed, placebo-controlled study of long-term therapeutic transfer of encapsulated … Ended recruitment
  2024-517132-22-00 5 2023-01-26 active ulcerative colitis
• An extension study of long-term efficacy, safety and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed pr … Ended recruitment
  2024-510818-33-00 5 2023-01-24 Chronic Spontaneous Urticaria
• Efficacy and Safety Study of Nipocalimab for Adults with Active Inflammatory Myopathies Ended recruitment
  2023-505314-20-00 4 2023-01-20 Active Idiopathic Inflammatory Myopathies (IIM)
• A study to test Taldefgropeb Alfa in patients with Spinal Muscular Atrophy. Ended recruitment
  2024-511852-42-00 5 2023-01-19 Spinal Muscular Atrophy
• Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Mult … Ended recruitment
  2022-500861-29-00 5 2023-01-12 Relapsed or Refractory Multiple Myeloma (RRMM)
• Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy Ended recruitment
  2022-500090-13-00 4 2022-12-29 Becker Muscular Dystrophy (BMD)
• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Early … Ended recruitment
  2024-515198-91-00 10 2022-12-20 Dominantly Inherited Alzheimer Disease (DIAD)
• AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compare … Ended recruitment
  2024-511625-55-00 6 2022-11-30 EGFRmutated/T790M Mutation negative non-squamous NSCLC
• OM 85 in Paediatric Recurrent Respiratory Tract Infections with Wheezing Lower Respiratory Illness Ended recruitment
  2024-511581-37-00 6 2022-11-25 Respiratory Tract Infections with Wheezing Lower Respiratory Illness
• A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N … Ended recruitment
  2024-510947-71-00 5 2022-11-21 Chronic Myeloid Leukemia
• Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. Ended recruitment
  2023-508284-77-00 5 2022-11-16 Generalized Myasthenia Gravis with autoantibodies against acetylcholin
• Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U … Ended recruitment
  2023-505772-30-00 5 2022-11-09 Melanoma
• A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i … Ended recruitment
  2023-509859-13-00 5 2022-11-09 Relapsed or Refractory Multiple Myeloma (RRMM)
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended recruitment
  2024-515637-14-00 5 2022-11-08 Cystic Fibrosis
• A study into the efficacy and safety of dazucorilant (CORT113176) in patients with Amyotrophic Lateral Sclerosis Ended recruitment
  2024-514082-19-00 4 2022-11-04 Amyotrophic Lateral Sclerosis

Showing 673–696 of 1,080 trials